Q2 2025 Management View CEO Todd Davis stated that "our new strategy at Ligand is working and producing tangible outcomes. Our second quarter results reflect strong momentum across our expanding ...

Orchestra BioMed announced today that it completed strategic transactions and equity offerings worth an expected $111.2 ...

Ligand expects full-year earnings in the range of $6.70 to $7 per share, with revenue in the range of $200 million to $225 million. This story was generated by Automated Insights ( ...

Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

Orchestra BioMed, based in New Hope, successfully raised $111 million in just five days to support the advancement of two of ...

Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to inve ...

Ligand Pharmaceuticals announced that its partner, Pelthos Therapeutics, has launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first FDA-approved at-home treatment for molluscum contagiosum ...

Contacts Ligand Pharmaceuticals Incorporated Simon Latimer [email protected] (858) 550-7766 Twitter: @Ligand_LGND LHA Investor Relations Bruce Voss [email protected] (310) 691-7100 ...

Contacts Ligand Pharmaceuticals Incorporated Patrick O’Brien [email protected] (858) 550-7893 Twitter: @Ligand_LGND LHA Investor Relations Bruce Voss [email protected] (310) 691-7100 Pfenex Inc ...

Ligand Pharmaceuticals Incorporated today announced the completion of its expected tax-free distribution of 100% of Ligand’ s interest in its subsidiary OmniAb on a pro rata basis to Ligand ...